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Vectorenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/ΔF-
HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined
with the internal proteins of human parainﬂuenza virus type 3 (HPIV3). Electron microscopy analysis of the
virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle
size and shape resembling those of HPIV3. When HPIV3/ΔF-HN/EboGP was inoculated via apical surface of an
in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when
applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue.
Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by
immunohistochemistry, but infectious HPIV3/ΔF-HN/EboGP could not be recovered from the lungs, blood, or
other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely
protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV.
Published by Elsevier Inc.Introduction
Ebola virus (EBOV), along with the closely related Marburg virus,
belongs to the family Filoviridae and causes sporadic outbreaks of
hemorrhagic fever in Central Africa, with a mortality rate of up to 88%
(reviewed in Sanchez et al., 2007). Multiple initial attempts to develop
vaccines against EBOV were unsuccessful, suggesting that protective
immunity against EBOV is not easily achievable. During the past
decade, however, vector approaches for the development of vaccines
against EBOV using adenoviruses, vesicular stomatitis virus (VSV),
human parainﬂuenza type 3 (HPIV3), and Venezuelan equine
encephalitis virus replicons have resulted in dramatic advances in
vaccine development; nonetheless, no approved vaccine against EBOV
exists so far (reviewed in Collins and Bukreyev, 2007). EBOV is
transmitted by contact of infected ﬂuids or tissues with mucosal
membranes or breaks in the skin (Geisbert and Jahrling, 2004; Jaax
et al., 1995, 1996); in addition, infection has been demonstrated in
non-human primates by aerosol administration of the virus (Johnson
et al., 1995). Thus, the development of a vaccine that induces a strongnc.local immune response in the respiratory tract in addition to systemic
immunity would be advantageous.
We previously developed a topical respiratory tract vaccine against
EBOV based on human parainﬂuenza virus type 3 (HPIV3), which is a
common pediatric respiratory pathogen (reviewed in Karron and
Collins, 2007). This involved modifying complete infectious HPIV3 by
adding an additional transcription cassette expressing EBOV GP. The
resulting virus, HPIV3/EboGP, efﬁciently infected guinea pigs and
nonhuman primates, induced strong systemic and local immune
responses in the respiratory tract, and conferred a high level of
protection against an intraperitoneal (IP) challenge with EBOV (Buk-
reyev et al., 2006, 2007). However, evaluation of various human
adenovirus type 5 and vaccinia virus-vectored vaccines (Barouch et al.,
2004; Casimiro et al., 2003; Fitzgerald et al., 2003; Kanesa-Thasan et al.,
2000; Lemckert et al., 2005; Sharpe et al., 2001; Sumida et al., 2004; Zhi
et al., 2006), including an adenovirus-vectored vaccine against EBOV
(Yanget al., 2003), in animalmodels and in clinical studiesdemonstrated
that preexisting immunity to the vector can abolish or greatly reduce the
immunogenicity of the expressed foreign antigen. This also is a potential
concern for an HPIV3-based vaccine, given the high seroprevalence for
HPIV3 due to natural exposure. This concern has been somewhat
ameliorated by the recent observation that, while the replication of
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been previously infected with HPIV3, the immunogenicity of the EBOV
GP insert was not greatly affected (Yang et al., 2008). However, it is not
unusual for studies in small experimental animals to provide overly
optimistic vaccine efﬁcacy data (Geisbert et al., 2002), and these results
remain to be conﬁrmed in a non-human primate model. Thus, it would
be useful to modify the HPIV3 vector to reduce its sensitivity to
restriction by pre-existing immunity.Fig. 1. Construction of HPIV3/ΔF-HN/EboGP, expressing the complete EBOV GP, and HPIV3/
protein. (A) Genome maps of, in descending order: complete infectious HPIV3; HPIV3/EboG
between the HPIV3 P andM genes, of a transcription cassette expressing the complete EBOV G
and HN genes; and HPIV3/ΔF-HN/EboGPct, which was derived from HPIV3/ΔF-HN/EboGP b
shown to the left. (B) Deletion of HPIV3 F and HN genes. The region of the HPIV3/EboGP geno
that are ﬂanked by horizontal lines indicating noncoding gene regions; gene junctions are ind
intergenic (IG) trinucleotide, and a ﬁlled arrowhead denoting a gene-start (GS) signal. The
introduced 6–11 nucleotides upstream of the HN GE signal is italicized. The deletion begins a
(C) Replacement of the CTof EBOV GPwith that of HPIV3 F. Top: the downstream part of EBOV
solid lines, respectively. Bottom:modiﬁed chimeric GP inwhich the GP CT has been replacedw
and MluI recognition sequences present in the EBOV GP transcription cassette and used for t
that BfuAI cuts outside of, and in this case upstream of, its recognition sequence).GP is the sole EBOV transmembrane envelope surface protein and
mediates both attachment to cellular receptors and fusion of the viral
envelope and the cellular plasma membrane (Sanchez et al., 2007). In
contrast, HPIV3 has two transmembrane envelope surface proteins,
the hemagglutinin-neuraminidase (HN) that mediates receptor
attachment, and the fusion protein (F) that is responsible for
membrane fusion (Collins and Crowe, 2007). Since HPIV3 HN and F
are the sole neutralization antigens of HPIV3, we explored theΔF-HN/EboGPct, expressing EBOV GP bearing the cytoplasmic tail (CT) of the HPIV3 F
P, which was previously derived (Bukreyev et al., 2006, 2007) from HPIV3 by insertion,
P; HPIV3/ΔF-HN/EboGP, which was derived from HPIV3/EboGP by deleting the HPIV3 F
y replacing the CT of EBOV GP with that of HPIV3 F. The genome nucleotide lengths are
me spanning the M, F, HN, and L genes is shown; ORFs are indicated as ﬁlled rectangles
icated as a ﬁlled bar denoting a gene-end (GE) signal, a short horizontal line denoting an
sequences at the deletion points are expanded above the diagram. A StuI site that was
t the fourth nucleotide following the M ORF and ends at the above-mentioned StuI site.
GP is shownwith the transmembrane domain (TM) and the CT indicated by dashed and
ith themuch longer CT fromHPIV3 F. The stop codon is depicted with an asterisk. BfuAI
he replacement are italicized with their cleavage sites indicated with arrowheads (note
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and instead contained EBOV GP as the sole surface protein combined
with the internal proteins of HPIV3. In the present study we report the
successful recovery of such a chimeric virus, HPIV3/ΔF-HN/EboGP. We
have characterized the viral particles by electron microscopy,
conﬁrmed the constellation of virion proteins expressed in infected
cells, tested the ability of the virus to grow in various cell lines,
determined the effect of HPIV3-speciﬁc neutralizing antibodies on
growth in vitro, and tested the effect of GP on the polarity of vector
infection in human ciliated airway epithelium (HAE). Finally, using theFig. 3. Analysis of puriﬁed virions of HPIV3, HPIV3/EboGP, and HPIV3/ΔF-HN/EboGP by
gel electrophoresis in conjunction with silver staining (A) or Western blotting using a
guinea pig antiserum raised against a DNAvaccine expressing EBOV GP (B). Lanes: 1 and
5, MagicMark XP (Invitrogen) with the corresponding molecular weights indicated to
the left; 2, HPIV3; 3, HPIV3/EboGP; 4, HPIV3/ΔF-HN/EboGP. The HPIV3 P, HN, N, F1 and
M bands are identiﬁed based on published proﬁles (Storey et al., 1984; Wechsler et al.,
1985) and the position of EBOV GP is indicated.
Fig. 2. Electron micrographs of negative-stained particles of HPIV3, HPIV3/ΔF-HN/
EboGP, and EBOV. Note that the envelope of HPIV3/ΔF-HN/EboGP is thinner than that of
HPIV3 and contains spikes that resemble those of EBOV rather than HPIV3. Conversely,
the shape of the HPIV3/ΔF-HN/EboGP particle resembles that of HPIV3 rather than
EBOV. The EBOV imagewas kindly provided by C. Humphrey and A. Sanchez (Centers for
Disease Control and Prevention, Atlanta, GA).guinea pig model, we have determined the extent of virus replication,
the organ distribution, and the immunogenicity and protective
efﬁcacy of this vaccine virus against EBOV challenge in vivo.
Results
Functional replacement of the HPIV3 HN and F proteins by EBOV GP as
the sole surface protein
We previously constructed HPIV3/EboGP (Fig. 1A), in which
complete recombinant HPIV3 was modiﬁed by insertion, between
the P and M genes, of the coding sequence for EBOV GP ﬂanked by
HPIV3 gene-start (GS) and gene-end (GE) transcription signals
(Bukreyev et al., 2006, 2007). In the present study, HPIV3/EboGP
was modiﬁed by deletion of the HPIV3 F and HN genes to create
HPIV3/ΔF-HN/EboGP (Figs. 1A, B), which encodes full length EBOV GP
(Sanchez et al., 1996; Volchkov et al., 1995) as the sole viral surface
protein. Thus, infectivity of this chimeric virus would depend on
incorporation of EBOV GP, which directs both attachment and fusion,
into the particle. EBOV GP is a type I transmembrane protein that has
an unusually short C-terminal cytoplasmic tail (CT) KFVF (Sanchez
et al., 1993) that bears no sequence similarity to the much longer 23
amino acid C-terminal CT of the type I HPIV3 F protein (Spriggs et al.,
1986), or the 31 amino acid N-terminal CT of the type II HPIV3 HN
protein (Elango et al., 1986). The efﬁciency of incorporation of a
foreign glycoprotein into a virus particle can be inﬂuenced by its CT,
such that replacement of the foreign CT with that from an
endogenous glycoprotein can increase incorporation (Tao et al.,
2000). Therefore, we also designed a second virus, HPIV3/ΔF-HN/
EboGPct, in which the CT of EBOV GP in HPIV3/ΔF-HN/EboGP was
replaced with that of HPIV3 F protein (Figs. 1A, C). Both new chimeric
constructs conformed to the “rule of six” (i.e., each genome length
was an even multiple of six nucleotides), and both were designed so
that the hexamer spacing of transcription signals was conserved (i.e.,
the ﬁrst and last genes, N and L, initiate at the second hexamer
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nucleotide) (Kolakofsky et al., 1998).
The HPIV3/ΔF-HN/EboGP virus (expressing complete EBOV GP)
was readily recoverable and viable. In contrast, while the HPIV3/ΔF-
HN/EboGPct virus (expressing GP modiﬁed with the CT of HPIV3 F)
was recoverable in multiple experiments as evidenced by clusters of
rounded cells, it could not be ampliﬁed sufﬁcient for its use in
further experiments and will not be considered further. In the
recovered, ampliﬁed HPIV3/ΔF-HN/EboGP virus, the regions that
had been modiﬁed as well as the entire EBOV GP were ampliﬁed by
RT-PCR and analyzed by sequencing, which conﬁrmed the expected
sequence and demonstrated a lack of adventitious mutations in
these regions.Fig. 4. Replication of HPIV3/ΔF-HN/EboGP in cell monolayers. (A) Plaque formation in LLC-
under methylcellulose for 6 days at 32 °C, ﬁxed, and analyzed immunostaining with rabbit an
virions (HPIV3/EboGP and HPIV3/ΔF-HN/EboGP panels). (B) Growth kinetics of HPIV3, HPIV3
an MOI of 3 PFU/cell during a 2-h adsorption period, washed three times, and incubated at 3
with fresh medium. Viral titers in the aliquots were determined by plaque titration in LLC-M
detection is 1.7 log10 PFU/ml, with the exception of day 1, for which it was 0.7 log10 PFU/ml. No
MK2 and A549 cells infected with HPIV3 and HPIV3/EboGP, the monolayers were completely
the two independent experiments performed are shown. Growth kinetics of HPIV3 and HPI
previous study (Bukreyev et al., 2006).Analysis of HPIV3/ΔF-HN/EboGP particles
We puriﬁed HPIV3/ΔF-HN/EboGP and HPIV3 by ultracentrifuga-
tion in sucrose step gradients and compared the morphology of the
virus particles by electronmicroscopy versus that of EBOV (Fig. 2). This
showed that the overall size and the shape of the HPIV3/ΔF-HN/EboGP
particles were similar to those of HPIV3; however, the envelope
resembled that of EBOV both with regard to the appearance of the
surface spikes (Sanchez et al., 2007) and in being approximately 50%
thinner than that of HPIV3.
Gradient-puriﬁed HPIV3/ΔF-HN/EboGP particles also were ana-
lyzed by gel electrophoresis under reducing and denaturing
conditions followed by silver staining (Fig. 3A) or Western blotMK2 cells by HPIV3, HPIV3/EboGP and HPIV3/ΔF-HN/EboGP. The cells were incubated
tiserum raised against puriﬁed HPIV3 virions (HPIV3 panel) or puriﬁed inactivated EBOV
/EboGP and HPIV3/ΔF-HN/EboGP in LLC-MK2, Vero and A549 cells. Cells were infected at
2 °C. Aliquots of the overlying mediumwere taken on days 1, 2, 3, 4, and 6 and replaced
K2 cells. Mean values±SE, based on three monolayers per virus, are shown. The limit of
te that for many time points, error bars cannot be seen due to the low variability. In LLC-
destroyed by day 6, and therefore medium aliquots were not collected. Data from one of
V3/EboGP in LLC-MK2 and Vero cells using low MOI (0.001 PFU) were determined in a
Fig. 5. Infection of an in vitro model of human airway epithelium (HAE) with HPIV3 (rows A and B), HPIV3/EboGP (rows C and D), and HPIV3/ΔF-HN/EboGP (row E): selected
representative cross-sectional images. HAE were inoculated from either the apical (left column) or basolateral surface (right column; note that the method used for basolateral
inoculation exposed both surfaces to infection, see the text), and were ﬁxed and analyzed by immunostaining on day 2 (HPIV3/EboGP) or day 4 (HPIV3, HPIV3/ΔF-HN/EboGP). Viral
antigenwas detected with rabbit antiserum raised against puriﬁed HPIV3 virions (rows B and C) or puriﬁed EBOV virions (rows A, D and E) as the ﬁrst antibody followed by a labeled
second antibody (red), and the nuclei were stained blue with DAPI. Treatment of HPIV3-infected HAE with the EBOV-speciﬁc antibodies did not result in antigen detection, as
expected (row A). Speciﬁcity of staining was also established in preliminary experiments (data not shown).
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Fig. 7. Replication of HPIV3, HPIV3/EboGP and HPIV3/ΔF-HN/EboGP in the lungs of
guinea pigs: virus titers in the lungs harvested on days 2 and 4 after IN infection at a
dose of 4×105 PFU per animal. Mean values±SE are based on ﬁve (HPIV3) or six (HPIV3/
EboGP, HPIV3/ΔF-HN/EboGP) animals per time point. No infectious HPIV3/ΔF-HN/
EboGP was recovered at either time point (limit of detection 1.5 log10 PFU/g).
Fig. 6. Growth kinetics of HPIV3, HPIV3/EboGP and HPIV3/ΔF-HN/EboGP on HAE.
Triplicate HAE cultures were inoculated with viruses at an MOI of 2 PFU via the apical or
basolateral and apical surfaces, viral supernatants from the apical or basolateral
compartments were harvested, and viral titers were determined by plaque titration in
LLC-MK2 cells. Means represent three samples per group±SE. For the samples below
the limit of detection, which was 1.7 log10 PFU/ml, the value two-fold below the limit
(1.4 log10 PFU/ml) was assigned for calculation of the means.
353A. Bukreyev et al. / Virology 383 (2009) 348–361analysis using an antiserum against EBOV GP (Fig. 3B). The silver-
stained gel pattern of gradient-puriﬁed HPIV3/ΔF-HN/EboGP parti-
cles (Fig. 3A, lane 4) lacked the HN and F1 proteins, as expected,
whereas these species were evident in preparations of HPIV3 and
HPIV3/EboGP (lanes 2 and 3, respectively; note that the F1 band was
much less visible for both HPIV3 and HPIV3/EboGP and was located
close to an unidentiﬁed more abundant band). Analysis by silver
staining (Fig. 3A) and Western blotting (Fig. 3B) also revealed the
presence of EBOV GP, which migrated slightly above the 120 kDa
marker band, in preparations of HPIV3/ΔF-HN/EboGP (lane 4) and
HPIV3/EboGP (lane 3), but not in the HPIV3 vector (lane 2).
Importantly, in both assays the GP band was substantially denser
in HPIV3/ΔF-HN/EboGP than in HPIV3/EboGP preparations: densi-
tometer analysis of the silver stained gel showed that the GP:N ratio
was 1.06 for HPIV3/ΔF-HN/EboGP compared to 0.66 for HPIV3/
EboGP. The nearly two-fold greater incorporation of GP into the
HPIV3/ΔF-HN/EboGP is likely attributable to the absence of the
HPIV3 HN and F envelope proteins.Growth of HPIV3/ΔF-HN/EboGP in cell culture monolayers
First, we compared the plaque size of HPIV3/ΔF-HN/EboGP with
that of HPIV3 and HPIV3/EboGP. LLC-MK2 monkey kidney cells were
infected with serial dilutions of the three viruses, covered with the
medium containing 0.8% methylcellulose and incubated for 6 days at
32 °C. Plaques were visualized by immunostaining with antibodies
raised against puriﬁed HPIV3, in the case of HPIV3, or antibodies
raised against puriﬁed, inactivated EBOV, in the case of HPIV3/ΔF-HN/
EboGP and HPIV3/EboGP. The HPIV3/ΔF-HN/EboGP plaques were
smaller than those of HPIV3, with an average diameter that was 36%
that of the HPIV3 plaques (Fig. 4A), suggesting attenuation of the
construct. The average diameter of plaques formed by HPIV3/EboGP
was 62% of HPIV3 plaques. Similar results were obtained with Vero
cells (not shown).
Unexpectedly, we found that HPIV3/ΔF-HN/EboGP formed plaques
more readily than HPIV3 or HPIV3/EboGP. In LLC-MK2 cells, 1.0 TCID50
of HPIV3 was found to be equivalent to 0.2 PFU, whereas 1.0 TCID50 of
HPIV3/ΔF-HN/EboGP was equivalent to 4.4 PFU, suggesting a 22-fold
difference in the efﬁciency of plaque formation (for comparison, 1.0
TCID50 of HPIV3/EboGP was equal to 0.6 PFU and thus more closely
resembled HPIV3). Thus, replacement of the F and HN proteins with
EBOV GP dramatically enhanced the ability of the virus to form
plaques, although those plaques were reduced in size compared to
those of HPIV3 and HPIV3/EboGP. The mechanistic basis for this effect
is unknown. In all of the experiments in this report, titers and inocula
were based on PFU, which amounts to 22-fold and 7.3-fold less HPIV3/
ΔF-HN/EboGP relative to HPIV3 and HPIV3/EboGP, respectively, than
had the titers and inocula been based on TCID50. This provided for a
conservative evaluation of the performance of this virus.
We then compared the growth kinetics of HPIV3/ΔF-HN/EboGP
with those of HPIV3 and HPIV3/EboGP in monolayer cultures of LLC-
MK2 and Vero monkey kidney cells and A549 human respiratory
epithelial cells following infection with an input MOI 3 PFU/cell
(Fig. 4B). In LLC-MK2 cells, the growth of HPIV3/ΔF-HN/EboGP was
delayed compared with the other viruses but increased steadily such
that, by day 6, the titer was high (8.7 log10 PFU/ml) and similar to that
of HPIV3. In Vero cells, growth of HPIV3/ΔF-HN/EboGP was indis-
tinguishable from that of HPIV3 and achieved a titer in excess of 7.0
log10 PFU/ml, whereas HPIV3/EboGP achieved a titer that was 10-fold
higher under these conditions. Efﬁcient replication in Vero cells is
important because they are an approved substrate for the manufac-
ture of vaccines for human use. In contrast, in human A549 cells,
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viruses and the titer never exceeded 6 log10 PFU/ml.
Infection using an in vitro model of human airway epithelium (HAE)
Next, we evaluated infection in an in vitro model of the human
airway epithelium (HAE). This model consists of primary cells from
clinical specimens that are grown and differentiated in vitro into a
polarized, pseudostratiﬁed, ciliated epithelium that is morphologi-
cally and functionally similar to the epithelium of the conducting
airways. HAE preparations frommultiple donors were inoculated with
HPIV3, HPIV3/EboGP (Bukreyev et al., 2006), or HPIV3/ΔF-HN/EboGP
at an MOI of 2 PFU/cell via the apical or basolateral surface. We note
that, due to the infection procedure (Materials and Methods),
inoculation of the basolateral surface also exposed the apical surface
to virus. At days 2 and 4 post inoculation, the cultures were ﬁxed and
viral antigens were detected in histological cross-sections using
antibodies against virion preparations of HPIV3 (Figs. 5B, C) or EBOV
(Figs. 5A, D, E). Following apical inoculation with HPIV3 (Fig. 5B, leftFig. 8. Immunohistochemical analysis of viral antigen distribution in guinea pig lungs on da
EboGP (E, F), or mock infection (B). (A, C, D) Viral antigen detected in bronchial epithelium.
Lack of viral antigen in a bronchus. Viral antigen is stained brown against a background ofside), mostly ciliated epithelial cells were positive for virus antigen,
consistent with previous ﬁndings (Zhang et al., 2005). Loss of cilia and/
or ciliated cells was noted by 4 days post-inoculation. Apical
inoculation with HPIV3/EboGP (Figs. 5C, D, left side) also resulted in
infected ciliated cells, although reduced in number. Based on analysis
of multiple HAE, the mean percentages±SE of infected ciliated cells
following apical inoculation with HPIV3 or HPIV3/EboGP were as
following: HPIV3, 83.3±7.1 (based on 5 preparations), and HPIV3/
EboGP, 48.1±5.8 (based on 8 preparations), Pb0.01. In contrast, apical
infection with HPIV3/ΔF-HN/EboGP resulted in only rare isolated
infected cells in the apical layer with no visible destruction of cells or
cilia (Fig. 5E, left side).
Basolateral inoculation (which exposed both surfaces to virus)
with HPIV3 did not detectably infect any basolateral cells, although
numerous ciliated cells of the apical surface were infected (Fig. 5B,
right side). Basolateral inoculation with HPIV3/EboGP (Figs. 5C, D,
right side) showed the same pattern as for HPIV3, except that non-
ciliated and non-apical cells (e.g., basal cells) also were occasionally
infected (not shown), suggesting EBOV GP may increase HPIV3y 2 after IN infection with 4×105 PFU of HPIV3 (A), HPIV3/EboGP (C, D), HPIV3/ΔF-HN/
(F) A focus of positive staining present in alveoli; an adjacent bronchiole is negative. (E)
hematoxylin counterstain; cells positive for the antigen are shown with green arrows.
Fig. 9. Serum antibody responses in guinea pigs 28 (ﬁlled bars) and 56 (cross-hatched
bars) days following inoculation with 4×105 PFU of HPIV3/EboGP given IN (group 1),
4×105 or 4×106 PFU of HPIV3/ΔF-HN/EboGP given IN (groups 2 and 3), 4×106 PFU of
HPIV3/ΔF-HN/EboGP given IM (group 4), the equivalent of 4×106 PFU of UV-inactivated
HPIV3/ΔF-HN/EboGP given IN (group 5) or IM (group 6), and 4×106 PFU of HPIV3 given
IN (group 7). (A) EBOV-speciﬁc antibody titers, determined by ELISA against inactivated
EBOV particles. (B) EBOV-speciﬁc 60% plaque reduction titers (day 28 only); 1 of 6
animals in group 2 and 3 of 6 animals in group 4 lacked detectable neutralizing
antibodies and were assigned values of 1:10 for the purpose of calculation. (C) HPIV3-
speciﬁc antibody titers, determined by HAI; the samples from groups 2–6 were below
the limit of detection and were assigned values of 1:20 for the purpose of calculation.
Results from all three assays are expressed as mean values±SE based on six animals per
groups 1–4, four animals per groups 5 and 6, and two animals per group 7 (this last
groupwas from a separate experiment that was included for comparison; meanwith no
SE). The differences between the groups 1 and 3 in the levels of the EBOV-speciﬁc ELISA
(A) and neutralizing (B) antibody responses are not signiﬁcant with the exception of the
ELISA titers on day 56, for which the difference is signiﬁcant (Pb0.05). ND, not done. A
second experiment with additional animals yielded similar results (not shown).
Statistical signiﬁcances of differences between the values for groups 1–4 are shown in
panel A (day 28 only) and panel B.
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infection with HPIV3/ΔF-HN/EboGP (Fig. 5E, right side), occasional
infected individual or clusters of cells were detected located in apical,
basolateral, and intermediate cell layers starting at day 4. These data
indicate that all three viruses infected apical cells of HAE, with the
order of efﬁciency being HPIV3NHPIV3/EboGP≫HPIV3/ΔF-HN/
EboGP, and that expression of EBOV GP conferred the ability to infect
the basolateral and intermediate layers of HAE. However, infection via
the apical surface never penetrated beyond the superﬁcial cells.
Little or no HPIV3 antigenwas detected in the cilia of infected cells
using this particular polyvalent HPIV3-speciﬁc antiserum, although in
a previous study using a monoclonal antibody speciﬁc to the HPIV3 F
protein, expression was observed in the cilia (Zhang et al., 2005). This
difference likely is a consequence of the use of different antibody
preparations in the two studies. Interestingly, in the present study,
cilia also were strongly stained with the anti-EBOV antibodies. Since
GP is the only EBOV antigen expressed by HPIV3/ΔF-HN/EboGP, this
speciﬁcally identiﬁed EBOV GP. The signiﬁcance of this regional
distribution of GP with regard to viral assembly and budding remains
to be determined.
In separate experiments, triplicate HAE cultures per virus were
inoculated via the apical or basolateral surface (the latter exposing
both surfaces), and the kinetics of viral growth in HAE determined
(Fig. 6). These experiments demonstrated that, following apical
inoculation, all three viruses were detected in the apical compartment
at all of the time points tested, although HPIV3/EboGP was somewhat
attenuated compared to HPIV3, and HPIV3/ΔF-HN/EboGP was even
further attenuated. This difference was generally consistent with the
number of virus-positive cells that were observed on days 2 and 4 in
the experiment shown in Fig. 5. In contrast, virus was not detected at
the basolateral side following apical inoculation (not shown). When
inoculation was by the basolateral route and samples were collected
from the apical surface, the titers of HPIV3 and HPIV3/EboGP rapidly
increased to high titers by day 3, indicative of robust viral replication
and shedding from the apical surface, whereas replication and
shedding of HPIV3/ΔF-HN/EboGP was barely detectable. These titers
presumably reﬂect exposure of the apical cells to the viruses. With
basolateral collection, intermediate viral titers (∼4 log10 PFU/ml) were
detected for each of the three viruses only on day 1, with little or no
virus at later time points. We note that there are several aspects
speciﬁc to inoculation of the basolateral surface that probably
enhanced the retention of the initial inoculum at that surface, namely:
the basal cells are not tightly coupled, the 30–40 μm polytetraﬂuo-
roethylene support underlying the basal surface likely reduced the
efﬁciency of the wash, and only a single wash was performed. Thus,
the titers on day 1 likely reﬂect residual inoculum, rather than de novo
virus replication. Taken together, these data suggest that the presence
of EBOV GP as a sole envelope protein in the HPIV3 virions resulted in
a limited infection of both the apical and basolateral surfaces of HAE,
with shedding detectable from the apical surface but not the
basolateral surface.
HPIV3/ΔF-HN/EboGP is completely resistant to HPIV3-speciﬁc
neutralizing antibodies
To determine the susceptibility of HPIV3/ΔF-HN/EboGP to the
HPIV3-speciﬁc antibodies, we combined 25 μl of Opti-MEM containing
104 PFU of HPIV3 or HPIV3/ΔF-HN/EboGP and 10% guinea pig
complement with 25 μl of Opti-MEM containing a 1:40 dilution of
serum from rabbits that had been hyper-immunized with puriﬁed
preparations of HPIV3; negative controls contained complement but
not serum. The mixtures were incubated for 1 h at 37 °C, and residual
infectivity was determined by plaque titration. The titers of infectious
HPIV3 determined for the samples that contained or lacked HPIV3-
neutralizing serum were b2.5 PFU (no residual infectivity detected)
and 1.4×103 PFU, respectively, indicating that HPIV3 was completelyneutralized by the antibodies, as expected, whereas the control had an
approximately 10-fold reduction that might reﬂect a non-speciﬁc
effect of the incubation and the presence of complement. In contrast,
the titers of HPIV3/ΔF-HN/EboGP from samples that contained or
lacked HPIV3-neutralizing serumwere 7.0×102 PFU and 5.0×102 PFU,
respectively, indicating a lack of sensitivity of the virus to HPIV3-
speciﬁc antibodies. This also was conﬁrmed during multi-cycle
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antibodies in the medium overlay at a dilution of 1:100 completely
restricted the replication of HPIV3 with no effect on HPIV3/ΔF-HN/
EboGP. In contrast, we previously showed that HPIV3/EboGP is
partially sensitive to HPIV3 antibodies in vitro (Bukreyev et al., 2006).
HPIV3/ΔF-HN/EboGP is highly attenuated in vivo
To evaluate HPIV3/ΔF-HN/EboGP replication in vivo, we infected
groups of guinea pigs with HPIV3, HPIV3/EboGP, or HPIV3/ΔF-HN/
EboGP by the IN route at a dose of 4×105 PFU. On days 2 and 4 post
infection, the animals were euthanized, the lungs were isolated and
homogenized, and virus titers were determined (Fig. 7). Interestingly,
no virus was detected in animals infected with HPIV3/ΔF-HN/EboGP,
whereas both HPIV3 and HPIV3/EboGP were readily recoverable,
although the titer of the latter virus was reduced by more than 2 log10
compared to HPIV3 on day 2, the peak of virus replication (Fig. 7).
Since HPIV3/ΔF-HN/EboGP was not detected by plaque titration of
the lung homogenates, we attempted to detect evidence of infection
by immunohistochemical analysis of organs isolated from infected
animals. Guinea pigs were infected with HPIV3, HPIV3/EboGP, or
HPIV3/ΔF-HN/EboGP by the IN route at a dose of 4×105 PFU. On day 2
after infection, the animals were euthanized and lungs and other
organs (listed below) were isolated, ﬁxed in formalin and embedded
in parafﬁn. Tissue sections were prepared and stained with rabbit
serum against puriﬁed HPIV3 virions, which reacts with various HPIV3
proteins, including the internal proteins (data not shown), and thus
would detect the internal proteins of HPIV3/ΔF-HN/EboGP. In animals
infected with HPIV3 or HPIV3/EboGP, viral antigen was detected in
bronchi and large bronchioles extending into inﬂammatory alveolar
lesions with a moderate amount of antigen in bronchi, and less in
smaller airways (Figs. 8A, C, D), as also was observed in a previous
study (Yang et al., 2008). With HPIV3/ΔF-HN/EboGP, viral antigen was
detected in various parts of the lungs, but the number of cells involved
was very low. Fig. 8F shows an example of a lung tissue section
positive for viral antigen: one focus of positive staining is present in
the alveoli, but an adjacent bronchus is negative. In addition,
examination of kidneys, liver, thymus, salivary glands, and mediast-
inal, mesenteric and popliteal lymph nodes revealed no histopatho-
logical changes or antigen for any of the three viruses (data not
shown). Taken together, these data conﬁrm the pneumotropism of
HPIV3 and HPIV3/EboGP and suggest that HPIV3/ΔF-HN/EboGP is
highly attenuated in vivo and did not detectably disseminate beyond
the respiratory tract.
Despite the high level of attenuation, HPIV3/ΔF-HN/EboGP
is immunogenic
We evaluated the immunogenicity of HPIV3/ΔF-HN/EboGP in
comparison with HPIV3/EboGP, for which protective efﬁcacy was
previously demonstrated in both guinea pigs and monkeys (Bukreyev
et al., 2006, 2007). Groups of guinea pigs were immunized by the INTable 1
Immunogenicity of HPIV3/ΔF-HN/EboGP in HPIV3-immune and HPIV3-naïve guinea pigs
Groupsa Titer of HPIV3-speciﬁc
HAI serum antibodies
(day 49)a
HPIV3-naïve b2
HPIV3-immune 10.5±1.0
a On day 0, animals were mock-infected (4 animals, HPIV3-naïve group) or infected IN wit
day 49 and analyzed for HPIV3-speciﬁc antibodies by HAI assay. These are expressed as me
b On day 49, both groups were immunized IN with 4×104 PFU of HPIV3/ΔF-HN/EboGP. Tw
and assayed by ELISA against inactivated EBOV. Titers are expressed as mean reciprocal log2
EboGP and analyzed in parallel were b2 log2.route with HPIV3 at a dose of 4×106 PFU (Fig. 9, group 7), or HPIV3/
EboGP at a dose of 4×105 PFU (group 1), or HPIV3/ΔF-HN/EboGP at a
dose of 4×105 or 4×106 PFU (groups 2 and 3), or by the intramuscular
(IM) routewith HPIV3/ΔF-HN/EboGP at a dose of 4×106 PFU (group 4).
The additional groups immunized with HPIV3/ΔF-HN/EboGP at 4×106
PFU were included because, as already noted, the PFU dose of this
virus converted to TCID50 is 7.3-fold lower than the equal PFU dose of
HPIV3/EboGP. To evaluate possible responses due to preformed
antigen in the virus inoculum, HPIV3/ΔF-HN/EboGP was inactivated
by UV irradiation and additional groups of animals were immunized
by the IN or IM route (groups 5 and 6) with the equivalent of 4×106
PFU. Serum samples were collected on days 28 and 56 after
immunization and tested for EBOV-speciﬁc antibodies by ELISA
against inactivated virions (Fig. 9, panel A) and an EBOV neutralization
assay (panel B), and for HPIV3-speciﬁc antibodies by HAI (panel C).
With regard to EBOV-speciﬁc serum ELISA titers (Fig. 9, panel A),
administration of HPIV3/ΔF-HN/EboGP by the IN route at doses of
4×105 and 4×106 PFU induced titers of 1:1100 and 1:1600,
respectively, on day 28 (Fig. 9A, groups 2 and 3, respectively). By
day 56, the antibody levels increased further to 1:6500 and 1:4600,
respectively. These levels are only 2–3 fold lower than that induced by
HPIV3/EboGP in the same experiment (3600 and 13,000 on days 28
and 56, respectively, group 1) despite the highly restricted replication
of HPIV3/ΔF-HN/EboGP compared to HPIV3/EboGP. IN inoculation
with the UV-inactivated HPIV3/ΔF-HN/EboGP control (group 5)
induced little or no response conﬁrming that, while replication of
HPIV3/ΔF-HN/EboGP was not detected based on virus titration of lung
homogenates (Fig. 7A), the immunogenicity of this virus depended on
genome replication. IM immunization with HPIV3/ΔF-HN/EboGP
(group 4) induced titers of 1:128 and 1:181 on days 28 and 56,
respectively, and thus was substantially less immunogenic than the IN
route. However, in a separate experiment (not shown), IM immuniza-
tion with HPIV3/ΔF-HN/EboGP induced a 6.4-fold greater (Pb0.05)
level of serum ELISA antibodies than IM immunization with HPIV3/
EboGP. IM immunization with the UV-inactivated HPIV3/ΔF-HN/
EboGP control (group 6) resulted in a low level response.
With regard to EBOV-neutralizing serum antibody titers (Fig. 9B),
responses were detected in 5 of the 6 animals immunizedwith HPIV3/
ΔF-HN/EboGP by the IN route at a dose of 4×105 (group 2), in all of the
animals immunized by the IN route at a dose of 4×106, and in 3 of 6
animals immunized by the IM route (group 5). The mean antibody
titers for these groups paralleled that detected by ELISA. A lack of
detectable serum EBOV-neutralizing antibodies, as seen here in some
animals, does not necessarily correlate with a lack of protection: we
did not evaluate neutralizing titers in our previous studies with
HPIV3/EboGP in guinea pigs and rhesus monkeys (Bukreyev et al.,
2006, 2007), but a study of vesicular stomatitis virus-vectored EBOV
GP in cynomolgusmacaques documented complete protection against
EBOV challenge in every animal even though neutralizing serum
antibodies were undetectable in all animals following vaccination
(Jones et al., 2005). With regard to HPIV3 HAI serum antibodies
(Fig. 9C), no response was detected in any group immunized withTiter of EBOV-speciﬁc serum ELISA antibodies following
administration of HPIV3/ΔF-HN/EboGP on
day 49b
Day 77 Day 105
8.0±0.8 10.0±0.4
6.5±0.5 8.5±0.6
h 1×105 PFU of HPIV3 (5 animals, HPIV3-immune group). Serum samples were taken on
an reciprocal log2 titers±SE.
enty-eight and 56 days later (days 77 and 105, respectively), serum samples were taken
titers±SE. Background titers in sera from animals not immunized with HPIV3/ΔF-HN/
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lack of the HN protein.
In a separate experiment, we also evaluated whether prior
infection with HPIV3 would reduce the immunogenicity of HPIV3/
ΔF-HN/EboGP, a question that we also recently investigated for
HPIV3/EboGP (Yang et al., 2008). This might occur, for example, if the
HPIV3 internal proteins common to HPIV3 and HPIV3/ΔF-HN/EboGP
induced signiﬁcant protective immunity effective against the latter
virus. Also, we tested a lower dose of the vaccine in order to compare
the response with that after immunizations with greater doses used
in the previous experiments. Guinea pigs were mock-infected
(4 animals) or infected (5 animals) IN with 1×105 PFU of HPIV3.
Forty-nine days later, serum samples were collected and analyzed for
HPIV3-speciﬁc HAI antibodies, and all of the animals were infected
IN with 4×104 PFU of HPIV3/ΔF-HN/EboGP (Table 1). Twenty eight
and 56 days later, serum samples were taken and analyzed for EBOV-
speciﬁc ELISA serum antibodies. The mean log2 titers of EBOV-
speciﬁc antibodies were only slightly (less than 3-fold) reduced in
HPIV3-immune group, compared to HPIV3-naive animals, with no
statistically signiﬁcant difference between the two groups at either
time point, which is similar to the results that we recently described
for HPIV3/EboGP (Yang et al., 2008).
IN immunization with HPIV3/ΔF-HN/EboGP prevents replication and
disease from a highly lethal IP EBOV challenge
To evaluate the protective efﬁcacy of HPIV3/ΔF-HN/EboGP, groups
of guinea pigs were infected by the IN route with 4×105 PFU of HPIV3,Fig. 10. Challenge with EBOV: guinea pigs were immunized IN with 4×105 PFU of HPIV3
(4 animals), 4×105 PFU of HPIV3/EboGP (4 animals), or 4×106 PFU of HPIV3/ΔF-HN/
EboGP (6 animals), and challenged 25 days later with 1,000 PFU of EBOV by the IP route.
(A) Percent change in body weight following EBOV challenge. Daily mean weights±SE
are shown expressed as a percentage of the weight on day 0.When one or more animals
in a group died, the SE was calculated based on the remaining live animals, with a
minimum of 3 animals per group. (B) Kaplan–Maier survival curves and clinical disease
scores. All of the animals immunized with HPIV3/ΔF-HN/EboGP or HPIV3/EboGP
survived, while all of the HPIV3-immunized (control) animals died. Disease signs were
observed only in the control group and were scored daily for each of the four animals as
follows: 1, rufﬂed fur, reduced activity, loss of body conditions; 2, labored breathing,
hunched posture, bleeding, marked lethargy; 2+, same as 2, but extremely severe. Each
row represents the daily scores for one of the four control animals in that group, ending
with a vertical line on the day of death. One animal shown in the bottom was
euthanized on day 9 due to severity of the disease.4×105 PFU of HPIV3/EboGP, or 4×106 PFU of HPIV3/ΔF-HN/EboGP. On
day 25 post immunization, the animals were challenged with an
otherwise uniformly lethal 1000 PFU dose of guinea pig-adapted
EBOV-Zaire (Connolly et al., 1999) by the IP route. The LD50/PFU ratio
of this clone of EBOV is unknown; we note that the values determined
for ﬁve other guinea pig-adapted strains of EBOV administered by the
IP route were N1 (Volchkov et al., 2000), suggesting that, in our case,
the IP challenge dose probably exceeded 1,000 LD50. Following
challenge, clinical observation and weighing of the animals were
performed daily (Fig. 10A). The challenge resulted inweight loss in the
HPIV3-immunized control animals starting at day 3, which was
followed by the appearance of clinical signs of EBOV infection starting
at days 3–5 (the clinical scoring is described in the legend to Fig. 10).
All the control animals died on days 6, 7, or 8; the one remaining
animal was euthanized on day 9 according to the approved animal use
protocol due to the severity of the disease. In contrast, animals
immunized with HPIV3/EboGP or HPIV3/ΔF-HN/EboGP showed no
disease signs, and all the immunized animals survived.
In a separate experiment, guinea pigs were immunized by the IN
route with 4×105 PFU of HPIV3 or 4×106 PFU of HPIV3/ΔF-HN/EboGP
(four animals per group). On day 28 after immunization, the animals
were challenged IP with 1000 PFU of guinea pig-adapted EBOV as
described above. On day 5 following challenge, the animals were
euthanized and blood, spleen, liver, and lung samples were collected
and analyzed for EBOV by titration. In all of the control HPIV3-
immunized animals, high levels of infectious EBOV were detected in
all tissues (mean±SE): in blood, 4.4±0.6 log10 TCID50/ml; in spleen,
6.3±0.4 log10 TCID50/g; in liver, 6.1±0.2 log10 TCID50/g, and in lungs,
4.2±0.4 log10 TCID50/g. In contrast, no virus was detected in any tissue
of any of the HPIV3/ΔF-HN/EboGP-vaccinated animals. Thus, immu-
nization with HPIV3/ΔF-HN/EboGP conferred solid protection against
IP challenge with a uniformly lethal dose of EBOV.
Discussion
We replaced the HN and F proteins of recombinant wild type
HPIV3 with the GP of EBOV. This resulted in a viable chimeric virus,
HPIV3/ΔF-HN/EboGP, with EBOV GP as its sole surface glycoprotein.
Interestingly, HPIV3/ΔF-HN/EboGP retained the general size and
shape of an HPIV3 particle, but its envelope thickness and spike
morphology resembled those of an EBOV particle. Even though HPIV3
and EBOV are from different virus families and lack relatedness
between the HN and F proteins versus GP, the chimeric virus
replicated in LLC-MK2 and Vero monkey kidney cells to titers similar
to that of HPIV3. Efﬁcient growth in Vero cells is particularly
important, since that provides an acceptable substrate for vaccine
manufacture.
We initially anticipated that EBOV GP might not be efﬁciently
incorporated into HPIV3 particles or might not be functional in the
foreign envelope. Therefore, we also constructed in parallel a version,
called HPIV3/ΔF-HN/EboGPct, in which the CT of EBOV GP was
replacedwith that of the HPIV3 F protein. This was done to address the
possibility that compatibility of the CT of GP with the internal proteins
of the HPIV3 particle might be important for the efﬁcient production
of infectious particles, as we had previously observed in a study where
the HN and F glycoproteins of HPIV3 were replaced with those of
HPIV2 (Tao et al., 2000). However, in the present study, this
modiﬁcation reduced rather than increased the efﬁciency of produc-
tion of infectious virus and was not further pursued. It may be that,
because the EBOV GP and HPIV3 F protein are not signiﬁcantly related,
the chimeric protein created between the two might not have folded
correctly or might have functioned suboptimally.
The polarity of viral budding from polarized epithelial cells can
greatly affect the pathogenicity of a virus. For example, in Sendai virus,
mutations that conferred the ability to bud from the basolateral
surface of the respiratory epithelium contributed to systemic disease
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apical surface (Tashiro et al., 1992). HPIV3, which causes highly
localized infections in the respiratory airways, replicates primarily in
the apical cells on the luminal surface of the respiratory epithelium, a
phenotype that was recapitulated during infection of HAE in vitro as
shown here and in previous work (Zhang et al., 2005). In contrast,
Marburg virus, a ﬁlovirus closely related to EBOV, is released from the
basolateral membranes of infected polarized epithelial cells, even
though its GP protein expressed alone or in the context of viral
infection is predominately transported to the apical surface (Sanger
et al., 2001). The presence of EBOV GP as the sole surface protein in
HPIV3/ΔF-HN/EboGP thus had the potential to change the budding
phenotype or tissue tropism of the vector. This possibility was
investigated here using a well characterized in vitro model of
polarized mucocilliary HAE (Pickles et al., 1998). The presence of
EBOV GP in HPIV3/EboGP and HPIV3/ΔF-HN/EboGP appeared to
confer the ability to infect cells of the basolateral surfacewhen applied
directly to that surface, albeit inefﬁciently, whereas HPIV3 did not
detectably infect the basolateral surface. However, expression of EBOV
GP did not confer the ability to spread from infected apical cells to
underlying cells. Whether HAE were infected on the apical or
basolateral surface, virus release from the basolateral surface
appeared to be insigniﬁcant. In addition, in guinea pigs inoculated
by the IN route, the presence of EBOV GP in HPIV3/ΔF-HN/EboGP or
HPIV3/EboGP did not result in a detectable systemic infection. The
VP40 (matrix) protein of Marburg virus was recently found to
contribute to the basolateral budding of the virus by retargeting the
GP protein from the apical to the basolateral membrane (Kolesnikova
et al., 2007). In the HPIV3 backbone lacking EBOV VP40, this
interaction would be lacking and presumably was not supplemented
by the internal HPIV3 proteins; indeed, EBOV GP accumulated
primarily at the apical surface of HAE. This is consistent with a
previous report for Marburg virus (Sanger et al., 2001). Interestingly,
the accumulation of GP was localized in the cilia.
AlthoughHPIV3/ΔF-HN/EboGP replicated to high titers in LLC-MK2
and Vero cells, it was highly attenuated in vivo. The high level of
immunogenicity of HPIV3/ΔF-HN/EboGP despite its poor replication
compared to HPIV3/EboGP might be due, at least in part, to the
formation of GP spikes on the surface HPIV3/ΔF-HN/EboGP particles
(Fig. 2). For example, in the case of the hemagglutinin of avian
inﬂuenza virus, trimers (which form virion spikes) were more
immunogenic than monomers, and multimeric spikes were the
most immunogenic form (Wei et al., 2008). Similarly, the abundant
display of GP spikes on HPIV3/ΔF-HN/EboGP particles compared to
their inefﬁcient incorporation into HPIV3/EboGP particles might
provide for greater immunogenicity.
Recently, a candidate vaccine virus against EBOV was described
based on recombinant vesicular stomatitis virus (VSV) in which the
VSV surface glycoprotein G was replaced by GP of EBOV (Garbutt et al.,
2004). This vaccine virus replicated 100- to 1000-fold less efﬁciently
than the VSV parent in vitro, although given the high efﬁciency of
replication inherent in the parental VSV backbone, vaccine manufac-
ture would still be feasible. A single IM inoculation of cynomolgus
macaques with 107 PFU of this VSV-based chimera resulted in a
transient viremia in most animals based on virus isolation, did not
induce detectable neutralizing serum antibodies in any animal (which
became detectable after the challenge), but conferred complete
protection in all animals against IM challenge with 1000 PFU of
EBOV (Jones et al., 2005). HPIV3/ΔF-HN/EboGP appeared to be
substantially more attenuated than the VSV-based construct based
on the lack of recoverable vaccine virus in any of the guinea pigs, an
experimental animal that is permissive for HPIV3 and EBOV. Despite
this high degree of attenuation, a single dose of 4×105 or 4×106 PFU of
HPIV3/ΔF-HN/EboGP induced EBOV-neutralizing serum antibodies in
5 of 6 and 6 of 6 animals, respectively, and was completely protective
against an IP EBOV challenge, as already noted. IM immunizationwith4×106 PFU of HPIV3/ΔF-HN/EboGP induced EBOV-neutralizing serum
antibodies in 3 of 6 animals, indicating that the vaccine was
substantially more immunogenic by the IN route. It will be important
to extend the evaluation of HPIV3/ΔF-HN/EboGP to non-human
primates.
As a candidate vaccine against EBOV, HPIV3/ΔF-HN/EboGP has
several advantages over its predecessor, HPIV3/EboGP, which
expresses HPIV3 HN and F in addition to EBOV GP as surface proteins.
First, HPIV3/ΔF-HN/EboGP had a nearly 2-fold greater incorporation of
GP into the particle, as compared to HPIV3/EboGP. This presumably
was due to a lack of competition with HN and F for packaging. The
absence of HN and F as competing antigens, and the presence of GP in
ordered spikes resembling those of a ﬁlovirus particle, also might
provide for increased immunogenicity. Second, because HPIV3/ΔF-
HN/EboGP lacks the HPIV3 HN and F neutralization antigens, it should
be more resistant than HPIV3/EboGP to pre-existing immunity against
HPIV3. We previously found that, in guinea pigs, immunity to HPIV3
from prior infection completely blocked the replication of a
subsequent dose of HPIV3/EboGP (Yang et al., 2008). Interestingly, in
this previous study, the HPIV3/EboGP-borne GP retained much of its
immunogenicity despite the lack of detectable replication by the
vector (Yang et al., 2008), but we note that immunogenicity in HPIV3-
immune non-human primates and humans remains to be determined.
Thus, HPIV3/ΔF-HN/EboGP provides an alternative should pre-exist-
ing immunity to the HPIV3 vector be a problem. Third, HPIV3/ΔF-HN/
EboGP is very highly attenuated, as already noted, and thus should be
very safe. Taken together, these data provide a strong case for pursuing
HPIV3/ΔF-HN/EboGP (in parallel with HPIV3/EboGP) as a vaccine
candidate for respiratory immunization against EBOV and warrants
testing in non-human primates.
Materials and methods
Design and construction of HPIV3/ΔF-HN/EboGP and
HPIV3/ΔF-HN/EboGPct
HPIV3/ΔF-HN/EboGP and HPIV3/ΔF-HN/EboGPct were designed to
express complete EBOV GP or EBOV GP bearing the cytoplasmic tail
(CT) of HPIV3, respectively, as the sole viral surface protein (Fig. 1A).
They were constructed from a previously-described full-length cDNA
encoding HPIV3/EboGP (Bukreyev et al., 2006), which consists of the
complete HPIV3 backbone inwhich a transcription cassette containing
the ORF for EBOV GP ﬂanked by HPIV3-speciﬁc gene-start (GS) and
gene-end (GE) transcription signals was inserted between the HPIV3 P
and M genes (Fig. 1A). The F and HN genes were deleted from HPIV3/
EboGP as follows (Fig. 1B): ﬁrst, the construct was modiﬁed by
insertion of a StuI site into the downstream non-coding region of the
HN gene between the open reading frame (ORF) and the gene-end
transcriptional signal (Fig. 1B). This was done by replacing the XhoI-
SphI fragment of the HPIV3/EboGP cDNA (both sites are unique and
located at positions 9519 and 13339 respectively) with the corre-
sponding fragment from the previously-constructed plasmid p3/7
(131)2G-Stu (Durbin et al., 2000), which contains a full-length cDNA of
HPIV3 in which three point mutations had been introduced to create
the above-mentioned StuI site (Durbin et al., 2000). This replacement
resulted in the plasmid HPIV3/EboGP-StuI. Next, we used PCR to
amplify and modify nucleotides 5506–6899 of HPIV3/EboGP cDNA, a
segment that spans the M ORF, so as to introduce a StuI site three
nucleotides downstream of the M ORF. This was done using the
forward primer ATTTCTTGCTGCAGCGATGG (positions 5506–5525 of
HPIV3/EboGP) and the reverse primer GATAGGCCTTTACTAGTTC-
CATTGTTTGA (the underlined sequence in the primer is complemen-
tary to the downstream end of the M ORF and the StuI site is in bold).
This PCR product was digested with PﬂM1 (an endogenous site
present at nucleotides 5537–5547 in the GP gene of HPIV3/EboGP) and
StuI and cloned into the PﬂMI–StuI window of HPIV3/EboGP-StuI. This
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EboGP cDNA. Construction of the cDNA encoding HPIV3/ΔF-HN/
EboGPct, in which the cytoplasmic tail (CT) of the GP protein was
replaced with that of HPIV3 F (Fig. 1C), was performed as follows: the
pGem-5Zf cloning vector (Promega Inc., Madison,WI) wasmodiﬁed to
remove its BfuA1 and Mlu1 restriction sites by replacing the SpeI–NsiI
fragment, containing the two sites, with an irrelevant SpeI–NsiI
fragment lacking the sites, resulting in the plasmid pGem-5Zf/Spe-
Nsi1. Next the NcoI–NcoI fragment of HPIV3/ΔF-HN/EboGP (positions
3734–6252, which includes the downstream end of the EBOV GP
gene) was cloned into the unique NcoI site of the plasmid pGem-5Zf/
SpeI–NsiI, resulting in the plasmid pGem-5Zf/EboGP/NcoI–NcoI. We
then ampliﬁed the coding sequence for the HPIV3 F gene CT by PCR
using primers that added EBOV sequence and cloning sites on either
end. The forward primer was GACAATGGATACCGGCAGGTATTGGAGT-
TACAGGCGTTGTAATTGCAGTTATCGCTTTATTCTGTATATGCAAGTATTA-
CAGAATTCAAAA (the underlined sequence encodes the upstream end
of the HPIV3 F CT, the remainder encodes the TM of EBOV GP, and a
naturally-occurring BfuAI recognition sequence is italicized) and the
reverse primer TCTTAAACGCGTATTATTTGTTTGTTAGTACAT (the
underlined sequence is complementary to that encoding the down-
stream end of the HPIV3 F CT, the remainder is downstream
noncoding sequence from the EBOV GP transcription cassette, and
an MluI site in the latter sequence is in bold). The PCR product was
digested with MluI and BfuAI and the fragment was used to replace
the corresponding MluI–BfuAI fragment of the EBOV GP segment in
plasmid pGem-5Zf/EboGP/NcoI-NcoI. This replaced the CT of EBOV GP
with that of HPIV3 F, resulting in the plasmid pGem-5zf/EboGP/Nco-
Nco-mod. Finally, the NcoI–NcoI fragment from this plasmid-borne
segment was used to replace the corresponding NcoI–NcoI fragment
of HPIV3/ΔF-HN/EboGP, resulting in cDNA encoding HPIV3/ΔF-HN/
EboGPct. The modiﬁcations in the cDNAs for HPIV3/ΔF-HN/EboGP and
HPIV3/ΔF-HN/EboGPct were conﬁrmed by sequence analysis, and
recombinant viruses were recovered in cell culture using previously-
described methods (Bukreyev et al., 2006). The recombinant HPIV3/
ΔF-HN/EboGP virus was ampliﬁed by three passages in LLC-MK2 cells
at 32 °C.
Cells, virus ampliﬁcation and titration and plaque staining
Stocks of HPIV3 and HPIV3/ΔF-HN/EboGP were prepared in LLC-
MK2 Rhesus monkey kidney cells (American Type Culture Collection,
Manassas, VA) with Opti-MEM medium (Invitrogen, Carlsbad, CA)
containing 2.5% fetal bovine serum (Invitrogen). Plaque titration of
HPIV3 and HPIV3/ΔF-HN/EboGP was performed as previously
described (Bukreyev et al., 2006). In some cases, the TCID50 (50%
tissue culture infectious dose) titer was determined by limiting
dilution in LLC-MK2 cells. The sensitivity of the viruses to rabbit
HPIV3-speciﬁc antibodies was evaluated using guinea pig comple-
ment (Cambrex Corporation, East Rutherford, NJ), as described in
Results. Growth kinetics of the viruses were determined in LLC-MK2
cells, African green monkey kidney Vero cells, and human type II
alveolar adenocarcinoma A549 cells (all from the American Type
Culture Collection) grown in Opti-MEMmedium containing 2.5% fetal
bovine serum (Invitrogen). For comparison of plaque morphology,
HPIV3 plaques were immunostained with anti-HPIV3 serum as above
(Bukreyev et al., 2006), and HPIV3/EboGP and HPIV3/ΔF-HN/EboGP
plaques were immunostained in parallel with a 1:1000 dilution of
rabbit antiserum prepared against puriﬁed EBOV (kindly provided by
Dr. A. Sanchez, Centers for Control and Prevention, Atlanta, GA).
Electron microscopy
HPIV3 and HPIV3/ΔF-HN/EboGP were puriﬁed by centrifugation in
30-60% sucrose step gradients as described previously (Bukreyev et al.,
2006). The puriﬁed viral particles were bound to 200-mesh Formvar/carbon-coated nickel grids (Electron Microscopy Sciences, Hatﬁeld,
PA) and negatively stainedwith 1% ammoniummolybdate. Grids were
examined using a model H7500 transmission electron microscope
(Hitachi High Technologies, Schaumburg, IL) at 80 kV. The images
were obtained with an XR100 digital camera system (Advanced
Microscopy Techniques, Danvers, MA).
Polyacrylamide gel electrophoresis, silver staining and Western blotting
Sucrose gradient-puriﬁed virus preparations were subjected to
polyacrylamide gel electrophoresis under reducing and denaturing
conditions using 4–12% gradient NuPAGE gels (Invitrogen). Silver
staining was done using the SilverQuest kit (Invitrogen) according the
manufacturer's recommendations. Western blotting was performed
by conventional methods using a guinea pig antiserum raised by
immunization with a DNA vector expressing EBOV GP, which was
generously provided by A. Sanchez (Centers for Disease Control and
Prevention, Atlanta, GA).
Human airway epithelium (HAE)
Tracheobronchial epithelial cells were obtained from clinical
specimens by the University of North Carolina at Chapel Hill Cystic
Fibrosis Center Tissue Culture Core under UNC Institutional Review
Board-approved protocols. Primary cells were expanded by one
passage on Vitrogen-coated plastic dishes, plated at 250,000 cells
per 12 mm Millicell culture insert (0.4 μm pore size, Millipore
PICM01250), and allowed to differentiate with an air–liquid interface
for 4 weeks as previously described (Zhang et al., 2005). For apical
inoculation, 2×106 PFU of HPIV3, HPIV3/EboGP or HPIV3/ΔF-HN/
EboGP in 100 μl of viral suspension (input MOI of 2 PFU/cell) were
applied to the apical surface of HAE, cultures were incubated at 37 °C
for 2 h, the inoculumwas removed, apical surfaces were washed twice
with 0.5 ml of phosphate buffered saline, and cultures were returned
to 37 °C. For basolateral inoculations, HAE inserts were inverted,
inoculated as above for 2 h, basolateral surfaces werewashed one time
with 1 ml of phosphate buffered saline, and the inserts were returned
to the original orientation. To determine growth kinetics of the
viruses, 200 μl aliquots of fresh medium were added to the apical
surfaces at speciﬁc time points, incubated for 30min, and harvested as
apical wash. Basolateral supernatants were also harvested and
replaced with fresh medium. The aliquots were frozen and plaque
titrated in LLC-MK2 cells. For identiﬁcation of the cell types infected
by viruses, HAE were ﬁxed with 4% paraformaldehyde, parafﬁn
embedded, and cut into 5 μm sections. Viral antigens were detected
with rabbit antiserum against puriﬁed HPIV3 or EBOV virions
(described above), and Alexaﬂuor-594 (red)-conjugated goat anti-
rabbit secondary antibody (Invitrogen). Nuclei were counter-stained
with Hoechst 33342 dye (Invitrogen). Fluorescent confocal images, as
well as optical differential interference contrast (DIC) images, were
obtained using a Leica SP2 AOBS Upright Laser Scanning Confocal
microscope and overlaid images were constructed using Adobe
Photoshop software (Adobe Systems, Inc., San Jose, CA).
Inoculation of animals and immunohistochemical analysis of tissues
Guinea pigs (3–4-week-old, strain Hartley, Charles River Labora-
tories [Wilmington, MA]) were conﬁrmed to be seronegative for
HPIV3 by hemagglutinin inhibition (HAI) assay using guinea pig
erythrocytes (30). IN inoculation was performed by applying 100 μl of
virus suspension in L-15 medium (Invitrogen) into each nostril under
mild anesthesia with methoxyﬂurane (Medical Developments Inter-
national Limited, Springvale, Australia). For intramuscular (IM)
inoculation, 100 μl of the viral suspension was injected into the
gastrocnemius muscle under light anesthesia. All procedures with
guinea pigs were performed in accordance with protocols and
360 A. Bukreyev et al. / Virology 383 (2009) 348–361guidelines approved by the NIH Animal Care and Use Committees and
were performed in facilities approved by the Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional. Immunohistochemical analysis of animal tissues was per-
formed as described previously (Yang et al., 2008) using rabbit serum
against puriﬁed HPIV3 virions, which stains HPIV3/ΔF-HN/EboGP
plaques almost as efﬁciently as HPIV3 or HPIV3/EboGP plaques due to
reactivity with both surface and internal HPIV3 proteins (data not
shown).
Analysis of antibody responses
EBOV-speciﬁc enzyme-linked immunosorbent assay (ELISA) was
performed as previously described (Yang et al., 2008) using puriﬁed
EBOV particles inactivated by gamma-irradiation (kindly provided by
Dr. A. Sanchez, Centers for Disease Control and Prevention, Atlanta,
GA) as an antigen. EBOV neutralizing antibody titers were determined
as previously described (Jahrling, 1999; Jones et al., 2005), except that
the endpoint was 60% plaque reduction rather than 80%. HPIV3-
speciﬁc antibody titers were determined by a hemagglutination
inhibition assay (HAI), as described previously (van Wyke Coelingh
et al., 1985).
EBOV challenge experiments
Experiments involving challengewith EBOVwere performed at the
biosafety level 4 facility of the Canadian National Microbiology
Laboratory. The experiments were approved by the Animal Care
Committee of the Canadian Science Centre for Human and Animal
Health (Winnipeg, Canada) following the guidelines of the Canadian
Council on Animal Care (Ottawa, Canada). Guinea pig adapted EBOV
species Zaire, which was produced by serial passages in animals until
uniformly lethal (Connolly et al., 1999), was administered by the IP
route at a dose of 1000 PFU. Following challenge, the animals were
weighed daily and disease was evaluated using the scoring system
described in the legend for Fig. 10. Analysis of EBOV in blood and in
internal organs was performed as previously described (Jones et al.,
2007). Mean EBOV titers in blood, spleen and liver were determined
based on one sample per animal from four animals in each group; viral
titers in lungs were determined based on one sample from each lung
(i.e., two samples per animal) from four animals per group. In the
HPIV3-immunized control group, EBOV was not detected in right lung
of one animal; for the purpose of calculation, a titer that was two-fold
below the limit of detection was assigned for this negative sample.
Statistical analysis of data
Differences were evaluated by Student's T-test and considered
signiﬁcant when Pb0.05. Data are shown as means±SE of the mean.
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